赛维健有奖征文启事

发布时间：2018-06-11 23:23

本文选题：叶酸制剂 + 多聚谷氨酸　；参考：《介入放射学杂志》2015年11期

【摘要】：正赛维健(注射用雷替曲塞,Raltitrexed)属叶酸结构类似物抗叶酸制剂,是直接、特异性胸苷酸合酶(TS)抑制剂。赛维健可被细胞膜主动摄取,在细胞内代谢为一系列多聚谷氨酸类化合物,药物原型和代谢产物均可发挥更强的抗肿瘤作用。长期临床观察发现,赛维健给药时间短、半衰期长达198小时、血管刺激性小、不良反应轻微,符合介入手术需求,且不需使用微量泵,减少感染风险,最大程度保证了患者生活质量。为了进一步探讨赛维健的科学应用,为临床上提供更有效的治疗方案,同时为广大介入医师提供一个交流学习平台,《介入放射学杂志》和南京正大天晴制药有限公司共同开展"赛维健有奖征文"
[Abstract]:Rotitrexide (for injection), a folic acid analogue, is a direct, specific thymidine synthase (TSX) inhibitor. Saivijian can be actively ingested by cell membrane and metabolized as a series of polyglutamic acid compounds in the cell. Both drug prototypes and metabolites can play a stronger antitumor effect. Long-term clinical observation showed that the administration time was short, the half-life was up to 198 hours, the blood vessel irritation was small, the adverse reaction was mild, and the need of interventional surgery was not required, and no micropump was needed to reduce the risk of infection. To the greatest extent, the quality of life of patients is guaranteed. In order to further explore the scientific application of Saivijian and provide a more effective treatment plan for clinical use, At the same time, it provides a platform for interventional physicians to exchange and study. The Journal of Interventional Radiology and Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. jointly launched the "Saivijian Award essay".
【分类号】：+

【相似文献】